These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
501 related articles for article (PubMed ID: 25533718)
1. The early predictive value of a decrease of metabolic tumor volume in repeated (18)F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy. Huang W; Liu B; Fan M; Zhou T; Fu Z; Zhang Z; Li H; Li B Eur J Radiol; 2015 Mar; 84(3):482-488. PubMed ID: 25533718 [TBL] [Abstract][Full Text] [Related]
2. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Huang W; Fan M; Liu B; Fu Z; Zhou T; Zhang Z; Gong H; Li B J Nucl Med; 2014 Oct; 55(10):1584-90. PubMed ID: 25214640 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369 [TBL] [Abstract][Full Text] [Related]
4. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer. Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651 [TBL] [Abstract][Full Text] [Related]
5. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069 [TBL] [Abstract][Full Text] [Related]
6. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281 [TBL] [Abstract][Full Text] [Related]
7. Standard uptake value and metabolic tumor volume of ¹⁸F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Huang W; Zhou T; Ma L; Sun H; Gong H; Wang J; Yu J; Li B Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1628-35. PubMed ID: 21617977 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer. Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127 [TBL] [Abstract][Full Text] [Related]
9. The predictive value of Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034 [TBL] [Abstract][Full Text] [Related]
10. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy. Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011 [TBL] [Abstract][Full Text] [Related]
11. (18)F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non-small cell lung cancer. Kurtipek E; Çayci M; Düzgün N; Esme H; Terzi Y; Bakdik S; Aygün MS; Unlü Y; Burnik C; Bekci TT Clin Nucl Med; 2015 Jun; 40(6):459-63. PubMed ID: 25742234 [TBL] [Abstract][Full Text] [Related]
12. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters. Chang S; Kim SJ Cancer Biother Radiopharm; 2016 Feb; 31(1):1-6. PubMed ID: 26844846 [TBL] [Abstract][Full Text] [Related]
13. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value. Satoh Y; Onishi H; Nambu A; Araki T Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640 [TBL] [Abstract][Full Text] [Related]
14. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer. Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis. Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer. Lin Y; Lin WY; Kao CH; Yen KY; Chen SW; Yeh JJ Anticancer Res; 2012 Nov; 32(11):5087-91. PubMed ID: 23155285 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma. Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784 [TBL] [Abstract][Full Text] [Related]
19. Significance of Kim E; Wu HG; Keam B; Kim TM; Kim DW; Paeng JC; Kim HJ; Chang JH Clin Lung Cancer; 2019 Jan; 20(1):e9-e23. PubMed ID: 30266585 [TBL] [Abstract][Full Text] [Related]
20. Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer. Dong X; Sun X; Sun L; Maxim PG; Xing L; Huang Y; Li W; Wan H; Zhao X; Xing L; Yu J PLoS One; 2016; 11(6):e0157836. PubMed ID: 27322376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]